Live Breaking News & Updates on Progressing Towards First Human Clinical Studies

Stay updated with breaking news from Progressing towards first human clinical studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Anatara Lifesciences Limited Company Summary & News ASX:ANR

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. ....

David Brookes , Steven Lydeamore , Anatara Lifesciences Limited , Company Appendix , Company Stage , Anatara Lifesciences Ltd , Lifesciences Limited , Bowel Syndrome , David Brookes Read Full Article , Annual Report , Read Full Article , Chief Executive Officer , Full Article , Investor Presentation , Successful Piglet Study , Monthly Activities Report , Chair Transition , Non Executive Director , Chairman Read Full Article , Lifesciences Ltd , Progressing Towards First Human Clinical Studies , Asx Anr , Australian Stock Exchange , Sin Au000000anr0 ,

Anatara Lifesciences Limited | Company Summary | ASX:ANR ISIN:AU000000ANR0 | Australian Stock Exchange ABN Newswire

Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara s human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.Read Full Article▸
On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.Read Full Article▸
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).Read Full Article▸ ....

David Brookes , Australian Taxation Office , Anatara Lifesciences Limited , Human Research Ethics Committee , Company Read Full Article , Anatara Lifesciences Ltd , Company Appendix , Government Research , Life Sciences Limited , Monthly Activities Report , Read Full Article , Chair Transition , Non Executive Director , Chairman Read Full Article , Life Sciences Ltd , Progressing Towards First Human Clinical Studies , Announces Australian Patent Grant , Full Article , Market Update , Unmarketable Parcel Share Buy Back , Buy Back Facility , Receives Ethics Approval , Gastrointestinal Re Programming , Federal Government , டேவிட் ப்ரூக்ஸ் , ஆஸ்திரேலிய வரிவிதிப்பு அலுவலகம் ,